Ulcerative Colitis
Most Ulcerative Colitis (UC) treatments suppress the immune system, risking infection, cancer, and eventual therapeutic resistance.
Piton redefines UC treatment
We take a new approach to UC treatment with a gut-targeted, non-immunosuppressive therapy that addresses the root cause of disease - not just inflammation - acting locally to minimize side effects and avoid the risks of systemic immune suppression.
The science behind our Ulcerative Colitis program
At Piton Therapeutics, we leverage large, multi-modal patient cohorts to discover efficacious treatments for broad patient populations.
Our solution
PTX-1059 is a small molecule inhibitor of host and bacterial proteases involved in Ulcerative Colitis.
Find out more about our Ulcerative Colitis program
At Piton Therapeutics, we are revolutionizing precision medicine through our state-of-the-art AI-powered platform, unlocking novel small-molecule therapeutics with unparalleled specificity.